Eli Lilly (LLY 0.67%) and Novo Nordisk (NVO 2.34%) are two of the most valuable healthcare stocks in the world, largely due to their successful diabetes and weight loss medications. They are also big players in the burgeoning GLP-1 weight loss market, and investors are paying large premiums for these stocks based on their potential.But what's intriguing is that the potential may be even bigger than what analysts and investors are expecting. And that's because there may be even greater benefits associated wi ...